Oculis Holding AG (NASDAQ:OCSAW – Get Free Report) was the target of a large drop in short interest during the month of June. As of June 30th, there was short interest totaling 4,485 shares, a drop of 43.2% from the June 15th total of 7,902 shares. Based on an average daily volume of 4,538 shares, the days-to-cover ratio is currently 1.0 days.
Oculis Trading Up 3.9%
OCSAW stock traded up $0.18 during midday trading on Friday, reaching $4.75. 4,414 shares of the company were exchanged, compared to its average volume of 6,014. Oculis has a one year low of $3.63 and a one year high of $22.64. The business has a 50-day moving average price of $9.30 and a two-hundred day moving average price of $13.09.
About Oculis
Oculis SA is a clinical‐stage biopharmaceutical company focused on developing disease‐modifying therapies for serious eye diseases. Utilizing its proprietary ocular formulation technologies, the company is advancing a pipeline of small‐molecule product candidates designed for topical or injectable delivery. Lead programs include OCS-01, a topical eye drop candidate for diabetic macular edema, and OCS-02, targeting diabetic retinopathy. Oculis also has OCS-05 in development for optic neuropathies and other retinal disorders, reflecting its commitment to addressing a broad spectrum of unmet needs in ophthalmology.
Founded in 2016 and headquartered in Geneva, Switzerland, Oculis operates research and development facilities in Europe and the United States.
See Also
- Five stocks we like better than Oculis
- AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector
- Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth
- TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident
- GE Aerospace Faces a Prove-It Moment in Q2 Earnings
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
